| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
1.13(B) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.58 - $15.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8.3 |
| Insider 3/6 Months : 8.9 |
|
| Guru Rank Number : 607 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
17,604 |
53,676 |
53,676 |
| Total Buy Value |
$0 |
$160,420 |
$460,539 |
$460,539 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
3 |
3 |
| Total Shares Sold |
226,641 |
507,557 |
529,791 |
1,205,966 |
| Total Sell Value |
$1,459,885 |
$5,741,044 |
$5,974,538 |
$13,645,593 |
| Total People Sold |
6 |
7 |
8 |
11 |
| Total Sell Transactions |
7 |
12 |
16 |
50 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Currie Mark G |
Chief Scientific Officer |
• – – |
2014-05-22 |
4 |
OE |
$0.60 |
$15,000 |
D/D |
25,000 |
335,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2014-04-24 |
4 |
AS |
$11.67 |
$291,750 |
D/D |
(25,000) |
310,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2014-04-24 |
4 |
OE |
$0.60 |
$15,000 |
D/D |
25,000 |
335,000 |
|
- |
|
| Conrades George N |
Director |
– • – |
2014-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
195 |
25,768 |
|
- |
|
| Shaw David Evans |
Director |
– • – |
2014-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
195 |
64,306 |
|
- |
|
| Roberts Bryan E |
Director |
– • – |
2014-03-14 |
4 |
A |
$12.76 |
$2,488 |
D/D |
195 |
24,555 |
|
- |
|
| Gilbert Halley E |
Chief Legal OfficerOfficer |
• – – |
2014-03-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,929 |
|
- |
|
| Roberts Bryan E |
Director |
– • – |
2014-02-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(931,248) |
0 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2014-02-20 |
4 |
OE |
$0.60 |
$135,000 |
D/D |
225,000 |
3,974,751 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2014-02-18 |
4 |
AS |
$14.43 |
$216,450 |
D/D |
(15,000) |
310,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2014-02-18 |
4 |
OE |
$0.60 |
$9,000 |
D/D |
15,000 |
325,000 |
|
- |
|
| Mchugh Julie |
Director |
– • – |
2014-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
6,775 |
6,775 |
|
- |
|
| Roberts Bryan E |
Director |
– • – |
2014-01-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(931,249) |
931,248 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2014-01-23 |
4 |
AS |
$14.38 |
$287,600 |
D/D |
(20,000) |
310,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2014-01-23 |
4 |
OE |
$0.60 |
$12,000 |
D/D |
20,000 |
330,000 |
|
- |
|
| Roberts Bryan E |
Director |
– • – |
2014-01-14 |
4 |
AS |
$12.57 |
$266,484 |
I/I |
(21,200) |
143,617 |
|
- |
|
| Roberts Bryan E |
Director |
– • – |
2014-01-13 |
4 |
AS |
$12.57 |
$3,198,349 |
I/I |
(254,443) |
147,000 |
|
- |
|
| Roberts Bryan E |
Director |
– • – |
2014-01-10 |
4 |
AS |
$13.12 |
$3,936,000 |
I/I |
(300,000) |
187,603 |
|
- |
|
| Roberts Bryan E |
Director |
– • – |
2014-01-09 |
4 |
AS |
$12.40 |
$3,334,447 |
I/I |
(268,907) |
235,476 |
|
- |
|
| Roberts Bryan E |
Director |
– • – |
2014-01-06 |
4 |
AS |
$12.06 |
$19,296 |
I/I |
(1,600) |
278,387 |
|
- |
|
| Roberts Bryan E |
Director |
– • – |
2014-01-03 |
4 |
AS |
$12.01 |
$646,739 |
I/I |
(53,850) |
278,642 |
|
- |
|
| Shaw David Evans |
Director |
– • – |
2014-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,339 |
64,111 |
|
- |
|
| Ebersman David A |
Director |
– • – |
2014-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,339 |
9,339 |
|
- |
|
| Cook Joseph C Jr |
Director |
– • – |
2014-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,339 |
50,578 |
|
- |
|
| Owens Edward P |
Director |
– • – |
2014-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,339 |
97,672 |
|
- |
|
931 Records found
|
|
Page 25 of 38 |
|
|
0.32 (5.16%) 
